Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06936878 · ClinicalTrials.gov registry record · NA

BOLSTER: Learning New Skills to Thrive

A NA study of Advanced Cancer and Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
600
Enrollment target
2
Study locations

NCT06936878 is a NA study of Advanced Cancer and Gynecologic Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 600 participants, above the 241-participant average among 122 other Advanced Cancer trials with a reported enrollment target (149% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06936878, a NA study of Advanced Cancer and Gynecologic Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
2
Study locations

Study Summary

This research study is evaluating a new program called Building Out Lifelines for Safety, Trust, Empowerment, and Renewal or (BOLSTER), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.

Interventions

  • BEHAVIORAL BOLSTER Program

Study Locations (2)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-05-12
Est. Completion 2028-02-29
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT06936878

The ClinicalTrials.gov registry entry for NCT06936878 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 241-participant average among 122 other Advanced Cancer trials with a reported enrollment target (149% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which BOLSTER Program is the first listed.

NCT06936878 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT06936878 about?

NCT06936878 is a clinical study titled "BOLSTER: Learning New Skills to Thrive". This research study is evaluating a new program called Building Out Lifelines for Safety, Trust, Empowerment, and Renewal or (BOLSTER), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.

What is the current status of trial NCT06936878?

This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2025-05-12. Estimated completion is 2028-02-29.

What conditions does trial NCT06936878 study?

This clinical trial studies the following conditions: Advanced Cancer, Gynecologic Cancer, Gastrointestinal Cancer.

What interventions are being tested in trial NCT06936878?

The interventions under investigation include: BOLSTER Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06936878?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06936878 being conducted?

This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.